Identification of a high-risk subtype of intestinal-type Japanese gastric cancer by quantitative measurement of the luminal tumor proportion

Cancer Med. 2018 Oct;7(10):4914-4923. doi: 10.1002/cam4.1744. Epub 2018 Aug 29.

Abstract

Background: We hypothesized that the relative proportion of tumor (PoT) at the luminal surface can predict gastric cancer (GC) patient survival.

Methods: We measured the luminal PoT in resection specimens from 231 GC patients with stage II/III disease who had surgery at the Kanagawa Cancer Center, Yokohama, Japan. Tissue microarrays were used to assess the extent of immune cell infiltration by CD45 immunohistochemistry. Results were related to histopathological features and patient overall survival (OS).

Results: PoT was significantly lower in diffuse-type (30%) compared to intestinal-type GC (41%), P = 0.03. Patients with low PoT intestinal-type GC survived significantly longer than patients with high PoT intestinal-type GC (5 years OS: 78% vs 47%, P = 0.0112). Low PoT was an independent favorable prognostic factor in multivariate analysis in intestinal-type GC. Low PoT was correlated with high content of CD45-positive immune cells (P = 0.035). There was no relationship between PoT and survival in diffuse-type GC.

Conclusions: This is the first study to identify a subgroup of patients with stage II/III intestinal-type GC at high risk of recurrence by measuring PoT at the luminal surface. The relationship between PoT and immune cell content provides an initial insight into potential underlying biological mechanisms.

Keywords: gastric cancer; intestinal-type; tumor proportion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Digestive System Surgical Procedures
  • Female
  • Humans
  • Intestines / pathology*
  • Japan
  • Leukocyte Common Antigens / metabolism*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery*
  • Survival Analysis
  • Tissue Array Analysis
  • Treatment Outcome

Substances

  • Leukocyte Common Antigens
  • PTPRC protein, human